US Patent

US8273876 — Medicaments containing vardenafil hydrochloride trihydrate

Method of Use · Assigned to Bayer Intellectual Property GmbH · Expires 2027-07-23 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for producing medicaments that contain vardenafil hydrochloride trihydrate in solid form.

USPTO Abstract

The invention relates to a method for producing medicaments that contain vardenafil hydrochloride, essentially as trihydrate in solid form, and to medicaments that can be obtained according to this method.

Drugs covered by this patent

vardenafil-hydrochloride (VARDENAFIL HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1288`	—	vardenafil-hydrochloride
`U-1288`	—	vardenafil-hydrochloride
`U-1288`	—	vardenafil-hydrochloride
`U-1288`	—	vardenafil-hydrochloride

Patent Metadata

Patent number: US8273876
Jurisdiction: US
Classification: Method of Use
Expires: 2027-07-23
Drug substance claim: No
Drug product claim: No
Assignee: Bayer Intellectual Property GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.